Clinical trial
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus…
NCT00137930 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00137930 |
|---|---|
| Title | Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis |
| Official title | Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Live attenuated rotavirus vaccine |
| Enrollment | 250 |
| Start date | Aug 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Aug 30, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: